Evaluation of Urinary Cytokines in Idiopathic Glomerulonephritis in a Tertiary Care Teaching Hospital
Keywords:
Urinary cytokines, Glomerulonephritis, MCP-1, IL-6Abstract
Background: Idiopathic primary glomerular diseases include a group of disorders characterized by pathologic alterations in normal glomerular structure and function, independent of systemic disease processes. Inflammatory cytokines, including MCP-1 and IL-6, plays an important role in glomerular inflammation. In this study we determined whether the measurement of urinary MCP-1 and IL-6 might be useful in assessing the role of these urinary marker in idiopathic primary glomerulonephritis and its relationship with histopathological finding. We found in result the minimum level of MCP-1 and IL-6 was 5.6pg/ml and 7.69pg/ml and the maximum level of MCP-1 and IL-6 was 23.6pg/ml and 60.04pg/ml respectively. The mean and standard deviation were higher in nephrotic range proteinuria than nonnephrotic proteinria. Correlation of urinary MCP-1 and IL-6 with 24 hour urinary protein <3.5gm and ≥3.5gm were analysed. The correlation between urinary IL-6 and histopathological finding of idiopathic primary glomerular diseases were found statiscally significant (p value <0.05). In conclusion, we found that level of urinary MCP-1 was raised in patients with increase degree of interstitial fibrosis and tubulointerstitial infiltrates and urinary IL-6 was noted in high level increase with increase degree of glomerlosclerosis, interstitial fibrosis and tublar atrophy.
Downloads
References
1. Rovin BH, Doe N, Tan LC Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis. 1996; 27: 640– 646.
2. Lepenies J, Eardley KS, Kienitz T, Hewison M, Ihl T, et al. Renal TLR4 mRNA expression correlates with inflammatory marker MCP-1 and profibrotic molecule TGF-beta in patients with chronic kidney disease. Nephron Clin Pract. 2011; 119: 97–104.
3. Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL- (Fas)lpr mice. J Am Soc Nephrol. 2007; 18: 2350–2358.
4. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin-6. Immunol. Today 1990; 11: 443–49. 5. Frank J, Engler-Blum G, Rodemann HP, Muller GA. Human renal tubular cells as a cytokine source: PDGF-B, GM-CSF and IL-6 mRNA expression in vitro. Exp. Nephrol. 1993; 1: 26–35.
6. Tabata C, Kubo H, Tabata R et al. All-trans retinoic acid modulates radiation-induced proliferation of lung fibroblasts via IL-6/ IL-6R system. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006; 290: 597–606
7. Ohta K, Takano N, Seno A et al. Detection and clinical usefulness of urinary interleukin-6 in the diseases of the kidney and the urinary tract. Cliii Nephrol. 1992; 38:185-189.
8. Ana Cristina Simõese Silva, André Barreto Pereira, MauroMartins Teixeira, and Antônio Lúcio Teixeira Chemokines as Potential
9. Hrvacevic R, Topalov D et al. Serum and urinary interleukin-6 levels in patients with primary glomerulonephritis. Srp Arh Celok. 1996; 124 suppl 1:40-2.
10. Rafid Tofik, Sophie Ohlsson, Omran Bakoush. Urinary Concentration of Monocyte Chemoattractant Protein-1 in Idiopathic Glomerulonephritis: A Long-Term Follow-Up Study. Plos one 2014 Jan 29; 9(1): e87857.
11. Minghui, Song Lu, Ma Dan et al. Clinical values of urinary IL-6 in asymptomatic hematuria and renal hematuria with proteins. Experimental and therapeutic medicine. 2013; 396-400.
12. 12.Stangou M, Alexopoulos E. et al Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nep hro-pathy. Nephrology. 2009 Sep;14(6):613-20.
13. Bazzi C, Rizza V, Casellato D, Stivali G, Rachele G, et al. Validation of some pathophysiological mechanisms of the CKD progression theory and outcome prediction in IgA nephropathy. J Nephrol. 2012; 25: 810–818.
14. Bergstein J, Leiser J and Andreoli S: The clinical significance of asymptomatic gross and microscopic hematuria in children. Arch Pediatr Adolesc Med 159: 353-355, 2005.
